In diabetes, a loss of pancreatic β-cells causes insulin dependency. When insulin dependency is caused by type 1 diabetes or pancreatic diabetes, for example, pancreatic β-cells need to be regenerated for definitive treatment. The methods for generating pancreatic β-cells include a method of creating pancreatic β-cells in vitro and implanting them into the body and a method of regenerating pancreatic β-cells in the body via gene introduction or the administration of differential proliferation factors to the body. Moreover, the number of pancreatic β-cells is also low in type 2 diabetes, caused by the compounding factors of insulin secretory failure and insulin resistance; therefore, if pancreatic β-cells can be regenerated in a living body, then a further amelioration of the pathology can be expected. The development of pancreatic β-cell-targeting regenerative medicine can lead to the next generation of diabetes treatment.
INTRODUCTION THE SIGNIFICANCE OF REGENERATIVE MEDICINE FOR DIABETES
For diseases caused by the failure of vital organs, the definitive treatment is to restore the organs' functions.
The status of diabetes is divided into three disease stages, according to the level of insulin action defi-This can be done by transplanting an organ provided by a third party, but this method relies on sufficient donors. ciency and the pathology: the normal zone, the boundary zone, and the diabetes zone. The diabetes zone is On the other hand, regenerative medicine, which aims to restore functionality that has once failed by applying divided into a period of insulin dependency in which the administration of insulin preparations is necessary knowledge from fields such as developmental biology, molecular biology, and stem cell biology to the medical for survival and a period of insulin nondependency. In type 1 diabetes, pancreatic β-cells are specifically de-field, is not dependent on the supply of donor organs, and therefore the clinical application of such treatments stroyed by autoimmune abnormalities, etc., resulting in insulin dependency. Moreover, a significant decrease offers great hope for the future. On the other hand, diabetes characterized by high blood glucose concentra-or loss of pancreatic β-cells due to chronic pancreatitis or pancreatic resection can lead to the same state. On tions is caused by a decreased insulin activity in the body, a known background factor of which is the loss the other hand, in type 2 diabetes, which develops through the compounding factors of insulin secretory or significant decrease of pancreatic β-cells that excrete insulin. Therefore, the regeneration of pancreatic β-cells failure and insulin resistance, insulin dependency is rarely caused, but it is known that the decrease of pan-is necessary for the definitive treatment of diabetes. This review article describes the regenerative medical strate-creatic β-cells is caused by glucose toxicity, exhaustion, and such. Insulin excreted from pancreatic β-cells gies that aim to treat diabetes by targeting pancreatic βcells, as well as other related issues.
is the only hormone that stimulates distal cells and tis-492 KOBAYASHI, YUASA, AND OKITSU sues and allows for the absorption of glucose that can REGENERATIVE MEDICAL APPROACHES AFTER THE DEPLETION OF ENDOGENOUS be used as source of energy. Therefore, the depletion of endogenous insulin secretion due to the loss of pan-
INSULIN SECRETION creatic β-cells causes metabolic abnormalities such as
There are two major methods of regenerating pancrehyperglycemia, thus leading to a poor prognosis for atic β-cells that have been lost. One is an ex vivo apsurvival.
proach in which pancreatic β-cells or insulin-producing Currently, simple blood glucose measurements and cells are created extracorporeally and transplanting them various types of insulin analogues have been developed, into the body (Fig. 1 ), and the other is an in vivo apand methods of controlling blood glucose levels have proach that aims to regenerate pancreatic β-cells inside advanced at a remarkable rate. However, even with the the body via gene introduction or the administration of full use of insulin secretion intensification therapy with differentiation-inducing factors (Fig. 2 ). multiple daily blood glucose measurements and the ad-Ex Vivo Approach (Fig. 1 ) ministration of corresponding amounts of insulin, many patients still experience unstable blood glucose levels.
With the ex vivo approach, cells are eventually returned to the body by transplantation, but because such This reflects the difficulty faced by current blood glucose measurement systems and insulin preparations in transplantable cells are already functional, the beneficial effects can be expected within a short period of time. fully regulating blood glucose, which is naturally performed by the living body. In a healthy body, pancreatic
Because an extracorporeal manipulation is applied, various operations can be performed on freely selected cells β-cells continuously detect blood glucose levels and immediately release appropriate amounts of insulin secre-that will become the source of pancreatic β-cells. Moreover, the issue of creating a supply of cells for transplan-tion into the blood properly to maintain the blood glucose level in the living body within a narrow range. It tation can also be addressed by creating them on a sufficiently large scale. The conditions for sources of is not difficult to understand why it is not easy to control blood glucose levels thoroughly with insulin ad-pancreatic β-cells used in the ex vivo approach include controllable proliferation and capabilities of the efficient ministrations only a few times a day based on blood glucose levels measured only a few times a day. Insu-expression of function and the maintenance of function. Embryonic stem cells and tissue stem/progenitor cells lin-dependent diabetes that exhibits unstable blood glucose with insulin therapy is associated with various are the most common candidates. It has been reported that, in a study using mice, glu-complications. More specifically, excessive dosages of insulin can lead to low blood glucose levels, so-called cose-sensitive insulin secretory cells were differentiated from stem cells and that diabetic status was ameliorated hypoglycemia, thereby causing insulin shock and thus posing a risk of endangering a patient's life. The main-by transplantation of the cells (8,12), but in general, it is recognized that it is still difficult to intentionally create tenance of higher blood glucose levels in order to avoid such a life-threatening condition results in the loss of pancreatic β-cells in mass quantities from embryonic stem cells and tissue stem/progenitor cells using the cur-vision caused by retinopathy, the need for dialysis due to chronic renal failure, and necrosis and amputation of rently available differentiation methods (7,17). In contrast, we established a cell line that secreted insulin in the lower limbs due to severe nerve and/or microvascular damage.
response to glucose concentrations with terminally differentiated human adult pancreatic islet β-cells as a cell The purpose of regenerating pancreatic β-cells in insulin-dependent diabetes is not to eliminate the daily source by applying a reversible immortalizing system (9,13). After performing a monolayer culture of human problems of insulin therapy. Rather, the purpose is to reinitiate the glycemia control that was originally per-pancreatic islets, it was immortalized using retroviral vectors SSR#69 that simultaneously encode SV40T and formed by the body itself by treating the root cause of insulin dependency as well as to resolve the issues re-fusion genes of hygromycin resistance (HygroR) and herpes simplex virus-thymidine kinase (HSV-TK) be-lated to the patient's survival that cannot be treated by insulin secretion therapy. Moreover, in type 2 diabetes, tween loxP sequences that are targeted by a Cre-recombinant enzyme, as well as recombinant retroviral vectors there are indications that insulin secretion failure is caused by decreased amounts of pancreatic β-cells (16) .
SSR#197 that express both hTERT, which prevents the shortening of telomere length, and an enhanced green Therefore, it is necessary to restore the number of pancreatic β-cells to regain the body's original ability to fluorescent protein (EGFP). The immortalized cells were selected with hygromycin and then screened with single-regulate blood glucose levels, and the necessity of developing regenerative medicine is being seriously consid-cell cloning to establish a human pancreatic β-cell line (NAKT-15). After infection of NAKT-15 cells with a ered. recombinant adenovirus vector AxCANCre that ex-manipulation on cells existing inside the body. It has been reported that in an experiment of gene therapy us-presses Cre recombinase, transplantation of the reverted form of NAKT-15 cells with immortalized genes re-ing rodents, diabetic symptoms such as the depletion of endogenous insulin secretion were alleviated. Lee et al. moved in diabetic mice resulted in regulation of blood glucose levels. cured a case of diabetes by inserting short-chain insulin genes downstream of glucose sensitive promoters, tar-Furthermore, Yamanaka, and coworkers have developed induced pluripotent stem cells (iPS cells) that have geting hepatocytes, into an individual suffering from a loss of pancreatic β-cells (11). Moreover, there are re-abilities equivalent to embryonic stem cells generated from adult human fibroblasts (21) . The problems faced ports claiming that the introduction of differentiation factor genes that target progenitor cells of pancreatic βwith embryonic stem cells are not all solved with iPS cells, due to the fact that a differentiation induction cells existing in the liver have restored the body's ability to regulate blood glucose levels (6,10). The in vivo ap-method for pancreatic β-cells is still needed. However, it circumvents the ethical issues regarding the use of hu-proach uses stem/progenitor cells that exist inside the body and can therefore be considered a more physiologi-man embryonic stem cells, and because the development of a method of differentiation induction for pancreatic cal approach. It does not require implantation techniques as in the ex vivo approach, and there is no need to con-β-cells from stem cells is expected to accelerate, future progress is also expected. sider ethical issues regarding cell sources. There are still many issues to be resolved regarding the aspects of effi-In Vivo Approach (Fig. 2) cacy and safety, such as confirmation of differentiation The in vivo approach is to create pancreatic β-cells or induction and control of proliferation, as well as assessglucose-sensitive insulin secretory cells by performing ments of systemic adverse effects caused by factors used for the operations. However, because it is physiologi-pancreatic β-cells (2,22). Moreover, Melton and coworkers have reported that adult pancreatic β-cells, cally more appealing and less invasive, it has been recognized as a useful approach and vigorous studies are which were assumed to not differentiate or proliferate, retain self-propagating abilities (5), thus indicating that currently under way. they may be sensitive to differential proliferation fac-REGENERATIVE MEDICAL APPROACHES tors. If the causal factors of decreases in the amount of BEFORE THE DEPLETION OF ENDOGENOUS pancreatic β-cells can be eliminated through an interven-INSULIN SECRETION tion in the early stages of diabetes, it is possible for the amount of pancreatic β-cells to recover to normal levels In type 2 diabetes, the amount of pancreatic β-cells decreases, but is not completely lost in most patients.
(14). Because it is not yet insulin dependent, medical treat-RELATED ISSUES REGARDING THE ment should therefore be minimally invasive. More spe-REGENERATION OF PANCREATIC ␤-CELLS cifically, the in vivo approach that involves the adminis-FOR COMPLETELY CURING DIABETES tration of differential proliferation factors and such targeting stem/progenitor cells in the pancreas is an ap-It is known that insulin secretory cells can be created ex vivo using stem cells as a cell source, but the capabil-propriate means. For example, the application of GLP-1 excreted from gut endocrine cells (L cells), which has ity of that of pancreatic β-cells is inferior in comparison to those generated in the original pancreatic islet (18) . It an insulin tropic effect, can be considered. Recent studies have reported that GLP-1 promotes differentiation has been clarified that a developed capillary net exists in the pancreatic islet (1) and that β-cells communicate into pancreatic β-cells and has a proliferative effect on 2. Brubaker, P. L.; Drucker, D. J. Minireview: Glucagon-like with other β-cells or non-β-cells to excrete hormones for peptides regulate cell proliferation and apoptosis in the blood glucose regulation (3,19). To create highly funcpancreas, gut, and central nervous system. Endocrinology tional pancreatic β-cells such as those existing in the 145: 2653-2659; 2004. body, it may be necessary to reproduce the tissue struc-
